An proposal worth 18.5 billion dollar has been revealed by Sanofi Aventis, which is a pharmaceutical company based in France for Genzyme which is a biotechnology enterprise based in United States which focuses on creating remedies and medication for uncommon ailments.

The offer provides a non-obligatory cash proposal of 69 dollars for each share of Genzyme which equals to about 39 % of the profits above the price of each share of the same at 49.86 dollar at the end of day on the 1st of July as the buzzes of annexation of the company had started spreading rapidly by then.

Sanofi describes the result of this probable acquisition as an enthralling prospect for both the companies and also the stakeholders of each company and claims this transaction to be a well-planned part of the premeditated progress of the company.

Describing this offer as just a proposal for the management of Genzyme, Sanofi has also affirmed that though this would not be termed as an aggressive offer, yet it is equipped to make use of all other options available with a view to close this deal productively.